In Vitro and in Vivo Anti-Diabetic Activity of Rhododendron Griffithianum for Insulin Dependent (Type I) Diabetes Mellitus

Abstract

Diabetes mellitus, a chronic metabolic disorder, poses a significant global health challenge, with the insulin-dependent (Type I) form requiring continuous therapeutic interventions. In this study, we investigate the potential anti-diabetic properties of Rhododendron griffithianum through both in vitro and in vivo assessments, targeting the specific needs of individuals with Type I diabetes. The in vitro phase involves the exploration of the inhibitory effects of Rhododendron griffithianum extracts on key enzymes involved in glucose metabolism, such as α-amylase and α-glucosidase. Additionally, the impact on glucose uptake in insulin-sensitive cells will be assessed to elucidate potential mechanisms of action at the cellular level. The in vivo component of the study employs an animal model of Type I diabetes to evaluate the efficacy of Rhododendron griffithianum in ameliorating hyperglycemia and associated complications. Diabetic animals will be treated with different doses of Rhododendron griffithianum extracts, and parameters including blood glucose levels, insulin sensitivity, lipid profile, and histopathological changes in pancreatic tissue will be examined. The findings from this research may provide valuable insights into the development of novel therapeutic agents for managing Type I diabetes. Moreover, the dual in vitro and in vivo approach enhances the translational relevance of the study, bridging the gap between laboratory discoveries and clinical applications. The results could potentially pave the way for the development of Rhododendron griffithianum-derived pharmaceuticals or nutraceuticals as adjunctive therapies for individuals with insulin-dependent diabetes.